Amongst sufferers with relapsed or refractory follicular lymphoma (FL), the therapy mixture of Monjuvi (tafasitamab-cxix) plus Revlimid (lenalidomide) and Rituxan (rituximab) has been...
Monjuvi plus Revlimid and Rituxan demonstrated improved progression-free survival for sufferers with relapsed or refractory follicular lymphoma, as introduced on the 2024 ASH...
One among this yr’s MPN Heroes® talked concerning the significance of a supportive care staff, particularly as each affected person with MPN presents...
